Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Ordinary Shares, no par value
-
Shares outstanding
-
156M
-
Number of holders
-
75
-
Total 13F shares, excl. options
-
44.5M
-
Shares change
-
+602K
-
Total reported value, excl. options
-
$89M
-
Value change
-
-$637K
-
Put/Call ratio
-
0
-
Number of buys
-
25
-
Number of sells
-
-46
-
Price
-
$2.00
Significant Holders of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) as of Q1 2022
98 filings reported holding WVE - Wave Life Sciences Ltd. - Ordinary Shares, no par value as of Q1 2022.
Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) has 75 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44.5M shares
of 156M outstanding shares and own 28.6% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (7.78M shares), M28 Capital Management LP (5.85M shares), MAVERICK CAPITAL LTD (5.59M shares), Bellevue Group AG (4.56M shares), PRIMECAP MANAGEMENT CO/CA/ (4.56M shares), Kynam Capital Management, LP (1.91M shares), PLATINUM INVESTMENT MANAGEMENT LTD (1.34M shares), D. E. Shaw & Co., Inc. (1.09M shares), Ikarian Capital, LLC (1.05M shares), and Artal Group S.A. (1M shares).
This table shows the top 75 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.